Teriflunomide for the treatment of multiple sclerosis

Seminars in Neurology

Volumn 33, Issue 1, 2013, Pages 45-55

  Oh, Jiwon ^a,b   O'Connor, Paul W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

clinical trials; multiple sclerosis; teriflunomide

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; LEFLUNOMIDE; PLACEBO; TERIFLUNOMIDE;

ADD ON THERAPY; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; EVOKED SOMATOSENSORY RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; CROTONATES; DRUG EVALUATION, PRECLINICAL; HUMANS; MULTIPLE SCLEROSIS; TOLUIDINES; TREATMENT OUTCOME;

EID: 84878326043     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1343795     Document Type: Article

References (54)

1. Marriott J. J., O'Connor P. W. Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials: 2010; 5 3 179 188
2. Osiri M., Shea B., Robinson V., et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev: 2003; 1 CD002047
3. Bartlett R. R., Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol: 1985; 7 1 7 18 (Pubitemid 15161142)
4. Korn T., Magnus T., Toyka K., Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol: 2004; 76 5 950 960 (Pubitemid 39458707)
5. Bruneau J. M., Yea C. M., Spinella-Jaegle S., et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J: 1998; 336 Pt 2 299 303 (Pubitemid 28564384)
6. Cherwinski H. M., Cohn R. G., Cheung P., et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther: 1995; 275 2 1043 1049 (Pubitemid 26025553)
7. Fox R. I., Herrmann M. L., Frangou C. G., et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol: 1999; 93 3 198 208
8. Rückemann K., Fairbanks L. D., Carrey E. A., et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem: 1998; 273 34 21682 21691 (Pubitemid 28405342)
9. Herrmann M. L., Schleyerbach R., Kirschbaum B. J. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology: 2000; 47 2-3 273 289 (Pubitemid 30394543)
10. Fairbanks L. D., Bofill M., Ruckemann K., Simmonds H. A. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem: 1995; 270 50 29682 29689
11. Elder R. T., Xu X., Williams J. W., Gong H., Finnegan A., Chong A. S. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol: 1997; 159 1 22 27 (Pubitemid 127493680)
12. Korn T., Toyka K., Hartung H. P., Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain: 2001; 124 Pt 9 1791 1802 (Pubitemid 32845440)
13. Siemasko K., Chong A. S., Jäck H. M., Gong H., Williams J. W., Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol: 1998; 160 4 1581 1588 (Pubitemid 28106441)
14. Xu X., Williams J. W., Bremer E. G., Finnegan A., Chong A. S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem: 1995; 270 21 12398 12403
15. Hoskin D. W., Taylor R. M., Makrigiannis A. P., James H., Lee T. D. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction. Int J Immunopharmacol: 1998; 20 9 505 513 (Pubitemid 28468598)
16. Manna S. K., Aggarwal B. B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol: 1999; 162 4 2095 2102 (Pubitemid 29288830)
17. González-Alvaro I., Ortiz A. M., Domínguez-Jiménez C., Aragón-Bodi A., Díaz Sánchez B., Sánchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis: 2009; 68 10 1644 1650
18. Mattar T., Kochhar K., Bartlett R., Bremer E. G., Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett: 1993; 334 2 161 164 (Pubitemid 23330574)
19. Manna S. K., Mukhopadhyay A., Aggarwal B. B. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol: 2000; 165 10 5962 5969
20. Hamilton L. C., Vojnovic I., Warner T. D. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol: 1999; 127 7 1589 1596 (Pubitemid 29368992)
21. Jankovic V., Samardzic T., Stosic-Grujicic S., Popadic D., Trajkovic V. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide. Cell Immunol: 2000; 199 2 73 80 (Pubitemid 30151745)
22. Zeyda M., Poglitsch M., Geyeregger R., et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum: 2005; 52 9 2730 2739 (Pubitemid 41369101)
23. Layseca-Espinosa E., Pedraza-Alva G., Montiel J. L., et al. T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol: 2003; 74 6 1083 1093 (Pubitemid 38040330)
24. Dimitrova P., Skapenko A., Herrmann M. L., Schleyerbach R., Kalden J. R., Schulze-Koops H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol: 2002; 169 6 3392 3399 (Pubitemid 35013189)
25. Déage V., Burger D., Dayer J. M. Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur Cytokine Netw: 1998; 9 4 663 668 (Pubitemid 29033934)
26. Cutolo M., Sulli A., Ghiorzo P., Pizzorni C., Craviotto C., Villaggio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis: 2003; 62 4 297 302 (Pubitemid 36363433)
27. Kraan M. C., de Koster B. M., Elferink J. G., Post W. J., Breedveld F. C., Tak P. P. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. Arthritis Rheum: 2000; 43 7 1488 1495 (Pubitemid 30452466)
28. Kraan M. C., Reece R. J., Barg E. C., et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum: 2000; 43 8 1820 1830
29. Fuentealba R. A., Marasa J., Diamond M. I., Piwnica-Worms D., Weihl C. C. An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet: 2012; 21 3 664 680
30. Limsakun T. M-VF. Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis. In: Neurology. Minneapolis, MN American Academy of Neurology: 2010
31. Tallantyre E., Evangelou N., Constantinescu C. S. Spotlight on teriflunomide. Int MS J: 2008; 15 2 62 68
32. Storch M. K., Stefferl A., Brehm U., et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol: 1998; 8 4 681 694 (Pubitemid 28460927)
33. Weissert R., Wallström E., Storch M. K., et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest: 1998; 102 6 1265 1273 (Pubitemid 28436287)
34. Korn T., Mitsdoerffer M., Kuchroo V. K. Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis. Results Probl Cell Differ: 2010; 51 43 74
35. Merrill J. E., Hanak S., Pu S. F., et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol: 2009; 256 1 89 103
36. Styren S. D., Barbier A. J., Selk D. E., Wettstein J. G. Beneficial effects of teriflunomide in experimental allergic encephalomyelitis. Abstract presented at: 34th Annual Meeting of the Society for Neuroscience; October 23-27, 2004; San Diego, CA
37. O'Connor P. W., Li D., Freedman M. S., et al. Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology: 2006; 66 6 894 900 (Pubitemid 43739766)
38. Confavreux C., Li D. K., Freedman M. S., et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler: 2012; 18 9 1278 1289
39. Freedman M. S., Wolinsky J. S., Wamil B., et al. Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology: 2012; 78 23 1877 1885
40. Freedman M. S WJ, Frangin G. A., Confavreaux C., et al. Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. In: Neurology. Minneapolis, MN American Academy of Neurology: 2010
41. U.S. National Institutes of Health Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta (TERACLES). Available at: http://clinicaltrials.gov/ct2/show/NCT01252355?term= teriflunomide&rank=3. Accessed July 23, 2012
42. U.S. National Institutes of Health Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00811395?term= teriflunomide&rank=4. Accessed July 23, 2012
43. O'Connor P., Wolinsky J. S., Confavreux C., et al. TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med: 2011; 365 14 1293 1303
44. U.S. National Institutes of Health Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis. Available at: http://clinicaltrials.gov/ct2/show/NCT00803049?term= teriflunomide&rank=13. Accessed July 23, 2012
45. Genzyme Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis. Available at: http://www.businesswire.com/news/home/20120531006926/ en/Genzyme-Reports-Positive-Top-Line-Results-TOWER-Pivotal. Accessed July 23, 2012
46. Genzyme Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis. Available at: http://www.businesswire.com/news/home/20111219006550/en/Genzyme-Reports-Top- line-Results-TENERE-Study-Oral. Accessed July 23, 2012
47. U.S. National Institutes of Health Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC). Available at: http://clinicaltrials.gov/ct2/show/NCT00622700?term= TOPIC&rank=1. Accessed July 23, 2012
48. Brent R. L. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology: 2001; 63 2 106 112
49. Fukushima R., Kanamori S., Hirashiba M., et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor leflunomide in mice. Reprod Toxicol: 2007; 24 3-4 310 316 (Pubitemid 350016756)
50. Chambers C. D., Johnson D. L., Robinson L. K., et al. Organization of Teratology Information Specialists Collaborative Research Group Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum: 2010; 62 5 1494 1503
51. Cassina M., Johnson D. L., Robinson L. K., et al. Organization of Teratology Information Specialists Collaborative Research Group Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum: 2012; 64 7 2085 2094
52. White D. H., Lynskey N. V., Jones P. B. Leflunomide use in New Zealand. A national prospective post-marketing study. Intern Med J: 2009; 39 2 95 102
53. Warnatz K., Peter H. H., Schumacher M., et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis: 2003; 62 1 50 57 (Pubitemid 36005795)
54. Gold R., Wolinsky J. S. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand: 2011; 124 2 75 84